Elutia Inc. (ELUT)vsEdwards Lifesciences Corp (EW)
ELUT
Elutia Inc.
$1.12
+5.66%
HEALTHCARE · Cap: $47.06M
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 49258% more annual revenue ($6.07B vs $12.29M). EW leads profitability with a 17.7% profit margin vs 4.3%. EW earns a higher WallStSmart Score of 55/100 (C).
ELUT
Hold43
out of 100
Grade: D
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ELUT.
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
16.2% revenue growth
Strong operational efficiency at 23.7%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
4.3% margin — thin
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ELUT
The strongest argument for ELUT centers on Price/Book, Revenue Growth. Revenue growth of 16.2% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bear Case : ELUT
The primary concerns for ELUT are EPS Growth, Market Cap, Return on Equity. Thin 4.3% margins leave little buffer for downturns.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Key Dynamics to Monitor
ELUT profiles as a growth stock while EW is a mature play — different risk/reward profiles.
EW carries more volatility with a beta of 0.93 — expect wider price swings.
ELUT is growing revenue faster at 16.2% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 43/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elutia Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?